13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
42 檔
38.7%
The Q4 2025 SEC filing reveals that Rosalind Advisors, Inc. held a total portfolio value of $269.2M, covering 42 public equity positions.
Rosalind Advisors, Inc. executed strategic sector rebalancing during Q4 2025, establishing 11 new positions while fully exiting 8 holdings and trimming 10 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 11.60% | +3.13% | — | |
| 2 | SVRA | Savara Inc | Stock-Other | 7.21% | +0.24% | -14.91% | |
| 3 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 7.07% | +5.54% | +25.84% | |
| 4 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 5.83% | +1.03% | +17.59% | |
| 5 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.92% | -1.97% | EXIT | |
| 6 | ✓ | Mediwound LTD | Stock-Other | 4.86% | -0.76% | — | |
| 7 | VSTM | Verastem Inc | Stock-Other | 4.85% | +1.11% | -7.31% | |
| 8 | REPL | Replimune Group Inc | Stock-Other | 4.82% | — | — | |
| 9 | ATYR | Atyr Pharma Inc | Stock-Other | 4.78% | — | — | |
| 10 | HELP | Cybin Inc | Stock-Other | 4.77% | +1.85% | +10.50% | |
| 11 | EYPT | Eyepoint Inc | Stock-Other | 4.43% | -0.12% | +6.15% | |
| 12 | CGON | Cg Oncology Inc | Stock-Other | 4.38% | -2.72% | EXIT | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.36% | — | -51.24% | |
| 14 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 3.66% | +0.25% | +68.71% | |
| 15 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.53% | — | — | |
| 16 | PROF | Profound Medical CORP | Stock-Other | 2.96% | -0.11% | +54.43% | |
| 17 | NSPR | Inspiremd Inc | Stock-Other | 2.44% | -1.54% | — | |
| 18 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.71% | — | — | |
| 19 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.53% | — | — | |
| 20 | TLPH | Talphera Inc | Stock-Other | 1.43% | +0.97% | -18.39% | |
| 21 | MYO | Myomo Inc | Stock-Other | 1.23% | +0.37% | +1.29% | |
| 22 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 1.06% | -0.42% | EXIT | |
| 23 | ✓ | Polypid LTD | Stock-Other | 1.06% | -0.32% | -24.18% | |
| 24 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.74% | -0.49% | — | |
| 25 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 0.66% | -0.39% | EXIT | |
| 26 | ✓ | Anavex Life Sciences CORP | Stock-Other | 0.66% | — | — | |
| 27 | ✓ | Regentis Biomaterials LTD | Stock-Other | 0.60% | +0.61% | — | |
| 28 | ✓ | Spdr Series Trust | Stock-Other | 0.47% | +0.01% | NEW | |
| 29 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 30 | ✓ | Ishares Tr | Stock-Other | 0.39% | +0.04% | NEW | |
| 31 | NRXS | Neuraxis Inc | Stock-Other | 0.37% | +0.42% | — | |
| 32 | KURA | Kura Oncology Inc | Stock-Other | 0.37% | +0.08% | — | |
| 33 | GUTS | Fractyl Health Inc | Stock-Other | 0.30% | — | -92.29% | |
| 34 | BFRI | Biofrontera Inc | Stock-Other | 0.23% | +0.07% | — | |
| 35 | ✓ | Arrivent Biopharma Inc | Stock-Other | 0.19% | — | EXIT | |
| 36 | ✓ | Verastem Inc | Stock-Other | 0.06% | — | -58.45% | |
| 37 | ✓ | Uniqure NV | Stock-Other | 0.03% | — | EXIT | |
| 38 | ✓ | Replimune Group Inc | Stock-Other | — | -1.10% | EXIT | |
| 39 | ✓ | Viking Therapeutics Inc | Stock-Other | — | — | — | |
| 40 | ✓ | Vistagen Therapeutics Inc | Stock-Other | — | — | — | |
| 41 | ✓ | Rezolute Inc | Stock-Other | — | — | — | |
| 42 | ✓ | Replimune Group Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SVRA | Savara Inc | +2.3% | -14.91% | Trim |
| 2 | ATYR | Atyr Pharma Inc | +2.2% | — | Unchanged |
| 3 | XFOR | X4 Pharmaceuticals Inc | +1.9% | +68.71% | Add |
| 4 | PROF | Profound Medical CORP | +1.8% | +54.43% | Add |
| 5 | HELP | Cybin Inc | +1.8% | +10.50% | Add |
| 6 | EYPT | Eyepoint Inc | +1.3% | +6.15% | Add |
| 7 | XERS | Xeris Biopharma Holdings Inc | +0.8% | +17.59% | Add |
| 8 | ✓ | Invesco QQQ Tr Put Option 06/2 | +0.5% | +80.00% | Add |
| 9 | BRD1EUR | Mind Medicine Mindmed Inc | +0.5% | — | Unchanged |
| 10 | VRDN | Viridian Therapeutics Inc | +0.5% | -25.00% | Trim |
| 11 | FENC | Fennec Pharmaceuticals Inc | +0.4% | +25.84% | Add |
| 12 | ✓ | Spdr S&P 500 Etf Tr Put Option | +0.4% | +70.00% | Add |
| 13 | ✓ | Ishares Tr | +0.4% | — | Unchanged |
| 14 | DCTH | Delcath Systems Inc | +0.3% | — | Unchanged |
| 15 | CGON | Cg Oncology Inc | +0.3% | — | Unchanged |
| 16 | ✓ | Mediwound LTD | +0.3% | — | Unchanged |
| 17 | ✓ | Spdr Series Trust | +0.2% | -8.96% | Trim |
| 18 | TRVI | Trevi Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | OCUL | Ocular Therapeutix Inc | +0.1% | — | Unchanged |
| 20 | TLPH | Talphera Inc | +0.1% | -18.39% | Trim |
| 21 | KURA | Kura Oncology Inc | +0.1% | — | Unchanged |
| 22 | MYO | Myomo Inc | +0.1% | +1.29% | Add |
| 23 | ✓ | Polypid LTD | 0% | -24.18% | Trim |
| 24 | ✓ | Replimune Group Inc | -0.1% | -54.85% | Trim |
| 25 | BFRI | Biofrontera Inc | -0.2% | — | Unchanged |
| 26 | ✓ | Rezolute Inc | -0.2% | — | Unchanged |
| 27 | ✓ | Verastem Inc | -0.3% | -58.45% | Trim |
| 28 | NSPR | Inspiremd Inc | -0.8% | — | Unchanged |
| 29 | VSTM | Verastem Inc | -1% | -7.31% | Trim |
| 30 | GUTS | Fractyl Health Inc | -2.4% | -92.29% | Trim |
| 31 | CYTK | Cytokinetics Inc | -3.2% | -51.24% | Trim |
| 32 | RZLT | Rezolute Inc | — | EXIT | Sold out |
| 33 | REPL | Replimune Group Inc | — | NEW | New buy |
| 34 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 35 | IDYA | Ideaya Biosciences Inc | — | EXIT | Sold out |
| 36 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 37 | ✓ | Atyr Pharma Inc | — | EXIT | Sold out |
| 38 | AVBP | Arrivent Biopharma Inc | — | NEW | New buy |
| 39 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 40 | ✓ | Anavex Life Sciences CORP | — | NEW | New buy |
| 41 | ✓ | Regentis Biomaterials LTD | — | NEW | New buy |
| 42 | CATBUSD | Astria Therapeutics Inc | — | EXIT | Sold out |
| 43 | NRXS | Neuraxis Inc | — | NEW | New buy |
| 44 | ✓ | Arrivent Biopharma Inc | — | NEW | New buy |
| 45 | ✓ | Ideaya Biosciences Inc | — | EXIT | Sold out |
| 46 | ✓ | Uniqure NV | — | NEW | New buy |
| 47 | ✓ | Scholar Rock Hldg CORP | — | EXIT | Sold out |
| 48 | ✓ | Viking Therapeutics Inc | — | NEW | New buy |
| 49 | ✓ | Replimune Group Inc | — | NEW | New buy |
| 50 | ✓ | Vistagen Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 42 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, SVRA, FENC) accounted for 38.7% of total reported equity market value during Q4 2025.
Top New Position Initiated
REPL
市值: $13.7M
Top Position Liquidated / Trimmed
RZLT
前期市值: $17.0M
During Q4 2025, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (11.6%)、SVRA (7.2%)、FENC (7.1%). The largest single position, DCTH, represented 11.6% of total portfolio value.
In Q4 2025, Rosalind Advisors, Inc. made 38 total portfolio adjustments, initiating 11 new buys, adding to 9 positions, trimming 10 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.